- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02980484
fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI
fMRI-neuronavigated Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depression Associated With Traumatic Brain Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
rTMS is an FDA-approved treatment for major depressive disorder, but its utility has not yet been investigated for major depression associated with traumatic brain injury.
This will be a prospective double-blind randomized sham-controlled crossover study. Patients in the treatment group will receive 20 sessions of high-frequency rTMS over the left dorsolateral prefrontal cortex (DLPFC) and low-frequency rTMS over the right DLPFC. The DLPFC will be identified as target by using individual subject-level resting state network estimation (Hacker et al, 2013). Patients in the control group will receive 20 sham treatments designed to be visibly indistinguishable from active treatment, and will subsequently have the option to be crossed over to receive active treatment with the aforementioned protocol. A subgroup of patients in each group will receive more detailed diffusion imaging (diffusion tensor and diffusion kurtosis imaging) and resting state fMRI scans before and after the treatment in order to assess for changes in white matter integrity and functional connectivity associated with the treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Adults age 18 to 65
- History of traumatic brain injury (TBI) at least two weeks prior to study initiation
- Presence of an active major depressive episode as defined by DSM-5 criteria, including depression secondary to traumatic brain injury
- Baseline score of 10 or greater on Montgomery-Asberg Depression Rating Scale (MADRS)
- Failure of at least one prior antidepressant trial after the traumatic brain injury
Exclusion criteria
History of:
- Moderate or severe substance use disorder in the past six months as defined by DSM-5 criteria, with the exception of cannabis and nicotine use disorders.
- Dementia, as defined by treating neurologist
- Moderate or severe autism spectrum disorder
- Bipolar disorder
- Schizophrenia spectrum disorders
Current evidence of:
- Substance-induced mood disorder
- Active psychotic symptoms
- Depression secondary to a general medical illness, with the exception of TBI
- Dysphoria better explained by a baseline personality disorder than a major depressive episode
- Dysphoria better explained by a baseline anxiety disorder (including post-traumatic stress disorder) rather than a major depressive episode
- Active suicidal ideation
Contraindications to rTMS treatment:
- Seizure disorder
- Significantly elevated seizure risk, as determined by clinician assessment
- TBI associated with elevated seizure risk, including penetrating injury and/or cortical intraparenchymal hemorrhage
- Presence of metallic objects within the head
- Presence of an implanted neurostimulation device within the head
Contraindications to MRI
- Severe claustrophobia
- Severe pain/illness exacerbated by lying prone in the scanner
- Presence of non-MRI compatible metal foreign bodies or implants
- Weight in excess of 350 lbs
- Shoulder width in excess of maximum tolerable width for scanner
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active rTMS
Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
|
Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train).
The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013).
Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
|
Sham Comparator: Sham/crossover rTMS
Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient.
After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
|
Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in depressive symptoms
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
This will be measured as the mean percentage change in baseline scores on Montgomery-Asberg Depression Rating Scale (MADRS) before treatment and immediately after the 4-week treatment period.
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in resting-state fMRI and DTI findings
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
MRI imaging will be conducted to assess resting-state functional connectivity using functional magnetic resonance imaging (fMRI).
More detailed structural (DTI) and functional (fMRI) imaging will be measured in a subgroup of patients.
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Changes in NIH Toolbox Cognitive, Emotional, and Quality of Life batteries
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
The NIH Toolbox Cognitive battery will be used to determine change in cognitive symptoms with treatment.
Emotional battery and TBI-QoL scales will be used to determine change in general neuropsychiatric symptom burden.
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Changes in temperament and character
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Will administer the 140-question Temperament and Character Inventory (TCI-R140) before and after treatment.
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Response and remission rates in depressive symptoms
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Percentage of subjects achieving response (>50% improvement in MADRS) and remission (final MADRS score <7) before treatment and immediately after the 4-week treatment period.
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Changes in headache scales
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Mean percentage improvement in HIT-6 headache scores
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Changes in tinnitus score
Time Frame: Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Mean percentage improvement in tinnitus severity score and mini-Tinnitus Questionnaire scores
|
Difference between pre-treatment (baseline) and post-treatment (4 weeks)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shan H Siddiqi, MD, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201603051
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
First Affiliated Hospital Xi'an Jiaotong UniversityXijing Hospital; Second Affiliated Hospital of Wenzhou Medical University; Central... and other collaboratorsRecruitingMTBI - Mild Traumatic Brain Injury | Moderate Traumatic Brain InjuryChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityHealth Science Center of Xi'an Jiaotong University; The Second Affiliated Hospital...RecruitingMTBI - Mild Traumatic Brain InjuryChina
-
Perception Dynamics InstituteUniversity of California, San Diego; University of South Alabama; University...RecruitingMTBI - Mild Traumatic Brain InjuryUnited States
Clinical Trials on Active
-
Unilever R&DCompleted
-
Novozymes A/SAnalyze & RealizeNot yet recruiting
-
Case Western Reserve UniversityHighland Instruments, Inc.RecruitingDiabetic Neuropathies | Chronic PainUnited States
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH); United States...CompletedChronic Low Back Pain | Chronic Neck PainUnited States
-
University of California, Los AngelesRecruiting
-
Lund UniversityVinnova; Antidiabetic Food Centre AFCCompleted
-
University Health Network, TorontoPatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Applied... and other collaboratorsActive, not recruitingDysphagiaUnited States, Canada
-
Chang Gung Memorial HospitalEnrolling by invitationSuspected Non-Alzheimer Disease Pathophysiology (SNAP)Taiwan
-
Sophiahemmet UniversityKarolinska Institutet; Linnaeus University; The Swedish School of Sport and Health... and other collaboratorsNot yet recruiting
-
University of California, Los AngelesUCLA Vatche and Tamar Manoukian Division of Digestive Diseases; UCLA Department...CompletedColorectal Neoplasms | Colorectal Cancer | Health ScreeningUnited States